Hansoh Pharmaceutical (03692) Receives Clinical Trial Notification for HS-10504 Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer

Hansoh Pharma (03692) announced that "HS-10504 Tablets," a Class 1 new drug independently developed by its subsidiaries, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Biomedical Science and Technology Co., Ltd., has received the clinical trial notification issued by the National Medical Products Administration of the People's Republic of China. The drug is intended for the treatment of advanced non-small cell lung cancer, with specific indications to be determined after clinical trials.